Pharma-Bio Serv (PBSV) Total Non-Current Liabilities (2017 - 2025)

Pharma-Bio Serv (PBSV) has 9 years of Total Non-Current Liabilities data on file, last reported at $1.7 million in Q3 2025.

• For the quarter ending Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Jul 2025 stood at $1.7 million (changed N/A YoY), and the FY2024 full-year result was $1.9 million, changed N/A from the prior year.
• Total Non-Current Liabilities for Q3 2025 stood at $1.7 million, down from $1.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $8.9 million in Q1 2021 and bottomed at $1.7 million in Q3 2025.
• The 5-year median for Total Non-Current Liabilities is $4.2 million (2022), against an average of $3.9 million.
• The widest annual swing landed in 2021, when Total Non-Current Liabilities surged 77.42%; it then tumbled 50.81% in 2022.
• A 5-year view of Total Non-Current Liabilities shows it stood at $5.0 million in 2021, then slumped by 50.81% to $2.5 million in 2022, then increased by 9.34% to $2.7 million in 2023, then slipped by 28.6% to $1.9 million in 2024, then declined by 13.42% to $1.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $1.7 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q4 2024), per Business Quant data.

Peer Comparison